Ceruvia Lifesciences Receives FDA Investigational New Drug Approval for Psilocybin Obsessive-Compulsive Disorder Program Phase 2 Trial

GREENWICH, Conn., June 27, 2022 -- (Healthcare Sales & Marketing Network) -- Ceruvia Lifesciences, a leading neurotransformational medicine biopharmaceutical company today announced that the U.S. Food and Drug Administration (FDA) has approved its Investi... Biopharmaceuticals, Neurology, FDA Ceruvia Lifesciences, psilocybin, obsessive-compulsive disorder
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news